Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Low-dose radiotherapy in indolent lymphoma.

Christine Rossier1, Ulrike Schick, Raymond Miralbell

  • 1Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

International Journal of Radiation Oncology, Biology, Physics
|March 15, 2011
PubMed
Summary

Low-dose involved-field radiotherapy effectively treats recurrent low-grade lymphoma and chronic lymphocytic leukemia (CLL), showing a 90% response rate and improved survival. Younger age and no prior chemotherapy are key positive factors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Consensus on the Management of Primary Localized Chordoma.

JAMA oncology·2026
Same author

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

Primary adrenal insufficiency in patients with bilateral adrenal metastases treated with curative ablative radiation therapy: A comprehensive review of literature and expert agreements for radiation practice.

Clinical and translational radiation oncology·2026
Same author

Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the EORTC-ESTRO radiotherapy infrastructure for Europe (E<sup>2</sup>-RADIatE) project.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

MR-guided stereotactic radiosurgery of an intracardiac tumoral thrombus using comprehensive motion management.

Clinical and translational radiation oncology·2026
Same author

Quality of Life and Clinical Outcomes in Patients with Skull Base Chordoma and Chondrosarcoma Treated with Pencil-Beam Scanning Proton Therapy.

Cancers·2025

Area of Science:

  • Oncology
  • Radiation Oncology
  • Hematology

Background:

  • Recurrent low-grade lymphoma and chronic lymphocytic leukemia (CLL) present management challenges.
  • Effective treatment strategies are crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of low-dose involved-field radiotherapy.
  • To assess response rates, duration of response, and overall survival.
  • To identify factors influencing treatment outcomes in patients with recurrent indolent lymphoma or CLL.

Main Methods:

  • A cohort of 43 patients with recurrent indolent lymphoma or CLL received low-dose involved-field radiotherapy (4 Gy).
  • Radiotherapy was administered either before or after chemotherapy.
  • Patient data on response, survival, and progression were analyzed.

Related Experiment Videos

Last Updated: Jun 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Main Results:

  • An overall response rate of 90% was observed, with 28% achieving complete response.
  • Median overall survival was 41 months for responders versus 6 months for progressive disease (p=0.001).
  • Factors like younger age, positive response, and no prior chemotherapy significantly improved outcomes.

Conclusions:

  • Low-dose involved-field radiotherapy is a highly effective treatment modality.
  • It offers significant benefits in managing recurrent low-grade lymphoma and CLL.
  • The treatment is associated with favorable response rates and prolonged survival.